Affiliation:
1. Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
Abstract
Abstract:
Macrovascular tumor thrombosis (MVTT) is common among patients with advanced
hepatocellular carcinoma (HCC), and it contains two main types, portal vein tumor thrombus
(PVTT) and hepatic vein tumor thrombus (HVTT). MVTT is a significant prognostic factor, and
the prognosis of HCC with MVTT remains unsatisfactory. The classification of MVTT varies in
different studies, and the management of HCC and MVTT differs among Eastern and Western
countries. Over the past years, a multidisciplinary approach, including surgical resection, radiotherapy,
and transcatheter arterial chemoembolization, especially the advent of new targeted drugs
and immune checkpoint inhibitors, has brought considerable survival benefits for HCC patients
with MVTT. Recently, multiple novel treatment strategies, such as neoadjuvant therapy or tumor
downstaging based on radiotherapy, immunotherapy, and molecular-targeted therapy, have broadened
the treatment landscape of MVTT. In this review, we conclude the consensus and progress
regarding diagnosis and treatment for patients with HCC and MVTT.
Funder
Clinical Research Plan of SHDC
State Key Program of National Natural Science Foundation of China
Science and Technology Commission Foundation of Shanghai Municipality
Publisher
Bentham Science Publishers Ltd.